$21.95
-0.15[-0.68%]
At close: Apr 26
$21.95
0[0.00%]
After Hours: 5:53PM EDT
Rocket Pharmaceuticals
(NASDAQ:RCKT)Rocket Pharmaceuticals Stock (NASDAQ:RCKT), Analyst Ratings, Price Targets, Predictions
Rocket Pharmaceuticals Inc has a consensus price target of $48.63, established from looking at the 46 latest analyst ratings. The last 3 analyst ratings were released from Needham, Goldman Sachs, and UBS on April 10, 2024, April 2, 2024, and March 1, 2024. With an average price target of $48.67 between Needham, Goldman Sachs, and UBS, there's an implied 121.72% upside for Rocket Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Needham
Goldman Sachs
UBS
JP Morgan
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Rocket Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | RCKT | Buy Now | Rocket Pharmaceuticals | $21.95 | 141.46% | Needham | Gil Blum | → $53 | Reiterates | Buy → Buy | Get Alert |
| 04/02/2024 | RCKT | Buy Now | Rocket Pharmaceuticals | $21.95 | 77.68% | Goldman Sachs | Richard Law | → $39 | Initiates | → Neutral | Get Alert |
| 03/01/2024 | RCKT | Buy Now | Rocket Pharmaceuticals | $21.95 | 146.01% | UBS | Colin Bristow | $56 → $54 | Maintains | Buy | Get Alert |
| 02/27/2024 | RCKT | Buy Now | Rocket Pharmaceuticals | $21.95 | 127.79% | JP Morgan | Eric Joseph | $55 → $50 | Maintains | Overweight | Get Alert |
| 02/27/2024 | RCKT | Buy Now | Rocket Pharmaceuticals | $21.95 | 196.13% | Cantor Fitzgerald | Josh Schimmer | $65 → $65 | Maintains | Overweight | Get Alert |
| 02/13/2024 | RCKT | Buy Now | Rocket Pharmaceuticals | $21.95 | 141.46% | Needham | Gil Blum | → $53 | Reiterates | Buy → Buy | Get Alert |
| 01/31/2024 | RCKT | Buy Now | Rocket Pharmaceuticals | $21.95 | 196.13% | Cantor Fitzgerald | Louise Chen | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 11/07/2023 | RCKT | Buy Now | Rocket Pharmaceuticals | $21.95 | 141.46% | Needham | Gil Blum | → $53 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2023 | RCKT | Buy Now | Rocket Pharmaceuticals | $21.95 | 196.13% | Cantor Fitzgerald | Josh Schimmer | → $65 | Initiates | → Overweight | Get Alert |
| 09/13/2023 | RCKT | Buy Now | Rocket Pharmaceuticals | $21.95 | 118.68% | Stifel | Dae Gon Ha | → $48 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | RCKT | Buy Now | Rocket Pharmaceuticals | $21.95 | 141.46% | Needham | Gil Blum | $60 → $53 | Maintains | Buy | Get Alert |
| 08/11/2023 | RCKT | Buy Now | Rocket Pharmaceuticals | $21.95 | 114.12% | Canaccord Genuity | Whitney Ijem | $49 → $47 | Maintains | Buy | Get Alert |
| 08/11/2023 | RCKT | Buy Now | Rocket Pharmaceuticals | $21.95 | 177.9% | Chardan Capital | Geulah Livshits | → $61 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | RCKT | Buy Now | Rocket Pharmaceuticals | $21.95 | 173.35% | Needham | Gil Blum | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | RCKT | Buy Now | Rocket Pharmaceuticals | $21.95 | 118.68% | Stifel | Dae Gon Ha | $53 → $48 | Maintains | Buy | Get Alert |
| 05/23/2023 | RCKT | Buy Now | Rocket Pharmaceuticals | $21.95 | 173.35% | Needham | Gil Blum | → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2023 | RCKT | Buy Now | Rocket Pharmaceuticals | $21.95 | 177.9% | Chardan Capital | Geulah Livshits | $63 → $61 | Maintains | Buy | Get Alert |
| 05/05/2023 | RCKT | Buy Now | Rocket Pharmaceuticals | $21.95 | 59.45% | Raymond James | Steven Seedhouse | $33 → $35 | Maintains | Outperform | Get Alert |
| 05/05/2023 | RCKT | Buy Now | Rocket Pharmaceuticals | $21.95 | 173.35% | Needham | Gil Blum | → $60 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Rocket Pharmaceuticals (RCKT)?
The latest price target for Rocket Pharmaceuticals (NASDAQ: RCKT) was reported by Needham on April 10, 2024. The analyst firm set a price target for $53.00 expecting RCKT to rise to within 12 months (a possible 141.46% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Rocket Pharmaceuticals (RCKT)?
The latest analyst rating for Rocket Pharmaceuticals (NASDAQ: RCKT) was provided by Needham, and Rocket Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Rocket Pharmaceuticals (RCKT)?
There is no last upgrade for Rocket Pharmaceuticals.
When was the last downgrade for Rocket Pharmaceuticals (RCKT)?
There is no last downgrade for Rocket Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Rocket Pharmaceuticals (RCKT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rocket Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rocket Pharmaceuticals was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating Rocket Pharmaceuticals (RCKT) correct?
While ratings are subjective and will change, the latest Rocket Pharmaceuticals (RCKT) rating was a reiterated with a price target of $0.00 to $53.00. The current price Rocket Pharmaceuticals (RCKT) is trading at is $21.95, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.